Freedom Capital Markets maintains Inspire Medical Systems at Buy, lowers price target to $93 from $97
Freedom Capital Markets kept Inspire Medical Systems' rating at Buy but reduced its price target to $93 from $97, a 4.1% decrease. This implies a 53.6% upside from the Nov 12 close of $60.54. Recent analyst price targets for the company range from $60 to $76.
How this was made

The 30-second read
Why it matters
A lower target may prompt short‑term selling pressure, but the effect is likely modest given the small magnitude.
Market read
Analyst target adjustment provides a minor trading signal for INSP.
What to watch
Potential pipeline developments or contract wins not mentioned could offset the downgrade.
Background
The article reports a recent analyst action on Inspire Medical Systems, noting a price target reduction.
Ticker impact
Freedom Capital Markets lowered its price target on Inspire Medical Systems to $93 from $97, indicating a fresh analyst downgrade.
likely modest price decline as investors price in the lower target
Target reduction signals reduced upside expectations; no other catalyst present.
Market effects
Minimal impact on the broader medical device sector.
No significant regional effect.
Limited relevance beyond the company.
Counterpoint
The target cut may be overly cautious if upcoming product launches exceed expectations.
Key entities
- analystFreedom Capital Markets
Equity research firm issuing the target cut.
- companyInspire Medical Systems
Medical device maker whose stock is affected.



